Relay Therapeutics, Inc.
As of Oct 22, 2026, Relay Therapeutics is in Stage 3, the topping phase, now in week 4 (since Sep 29, 2026). It closed at $18.34, 11.6% below its 52-week high and above its 200-day average, which is rising.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RLAY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RLAY among Biotechnology25th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …25 | RLAY | Stage 3 · wk 4 | 97 | +1.7% |
Relay Therapeutics: quick answers
What stage is Relay Therapeutics in?
As of Oct 22, 2026, Relay Therapeutics (RLAY) is in Stage 3, the topping phase. It entered Stage 3 on Sep 29, 2026 and is in week 4. What the four stages mean
Is Relay Therapeutics in an uptrend?
Its uptrend has stalled. Relay Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 25.0% above its 200-day average, which is rising.
How far is Relay Therapeutics from its 52-week high?
Relay Therapeutics closed at $18.34 on Oct 22, 2026, 11.6% below its 52-week high of $20.75. Its 52-week low is $6.05.
How has Relay Therapeutics performed over the past year?
As of Oct 22, 2026, Relay Therapeutics is up 160.5% over the past year and up 124.2% so far in 2026.
Which sector and industry is Relay Therapeutics in?
Relay Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.